Get startedLog in
    Picture of Phaxiam Therapeutics SA logo

    PHXM — Phaxiam Therapeutics SA Cashflow Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Phaxiam Therapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

    2018
    December 31st
    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-38.2-62.7-73.3-53.8-0.228
    Depreciation
    Non-Cash Items-1.460.2195.78-1.2-28.6
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-0.38814.910.8-7.15-7.58
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Taxes Payable
    Change in Other Liabilities
    Net Change in Other Assets & Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-39.3-43.3-51.7-56.8-31.8
    Capital Expenditures-14.2-20.1-1.14-0.298-0.085
    Purchase of Fixed Assets
    Other Investing Cash Flow Items-0.8150.279-0.336-0.04738.2
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Change in Net Intangibles
    Other Investing Cash Flow
    Cash from Investing Activities-15-19.8-1.48-0.34538.1
    Financing Cash Flow Items—1.71-0.138-0.374-0.223
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-0.8180.0425.444.7-1.77
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-51.1-61.2-28.7-10.75.09